Barclays PLC Grows Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Barclays PLC boosted its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 18.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 352,494 shares of the company's stock after buying an additional 56,110 shares during the period. Barclays PLC owned approximately 0.11% of Amneal Pharmaceuticals worth $2,792,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of AMRX. JPMorgan Chase & Co. raised its stake in shares of Amneal Pharmaceuticals by 149.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock valued at $10,792,000 after purchasing an additional 777,568 shares during the period. Raymond James Financial Inc. purchased a new position in Amneal Pharmaceuticals during the 4th quarter valued at about $2,946,000. Prudential Financial Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 29.6% in the fourth quarter. Prudential Financial Inc. now owns 1,183,781 shares of the company's stock worth $9,376,000 after buying an additional 270,200 shares in the last quarter. Trexquant Investment LP boosted its position in shares of Amneal Pharmaceuticals by 93.2% in the fourth quarter. Trexquant Investment LP now owns 462,720 shares of the company's stock valued at $3,665,000 after acquiring an additional 223,158 shares during the period. Finally, Vanguard Group Inc. grew its stake in Amneal Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 14,841,969 shares of the company's stock valued at $117,548,000 after acquiring an additional 218,025 shares in the last quarter. Institutional investors own 31.82% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on AMRX shares. Barclays increased their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, March 3rd. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $10.80.

Amneal Pharmaceuticals Stock Performance

AMRX traded down $0.36 during trading on Monday, reaching $7.61. The stock had a trading volume of 406,360 shares, compared to its average volume of 1,410,762. The business has a 50-day moving average of $8.02 and a 200-day moving average of $8.16. Amneal Pharmaceuticals, Inc. has a one year low of $6.29 and a one year high of $9.48. The stock has a market cap of $2.36 billion, a PE ratio of -11.18 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Friday, May 2nd. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.14 by $0.05. The firm had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. Equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the transaction, the director now directly owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. The trade was a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now owns 48,578,209 shares of the company's stock, valued at $405,628,045.15. This represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.56% of the stock is owned by corporate insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.